Recent Updates
Recently added Catalysts

mPnC candidate

Phase 2

Healthy Participants | Monoclonal antibody | Other |Pfizer, Inc.|Last Updated: May 8, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment105
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06116591A Phase 2 Study to Learn About a Monovalent Pneumococcal Conjugate Candidate in Healthy ToddlersPHASE2 COMPLETED 105Nov 8, 2023May 27, 2024May 8, 202511 Finland, Poland
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percentage of Participants With Local Reactions Within 7 Days After Dose 1
Day 1 through Day 7, where Day 1 is the day of Dose 1 administration (Visit 1 of study)

Local reactions included redness, swelling and pain at injection site. Redness and swelling were graded as mild: \> 0 to 2.0 centimeter (cm), moderate: \>2.0 to 7.0 cm, severe: \>7.0 cm and Grade 4: necrosis or exfoliative dermatitis (redness) and necrosis (swelling). Pain at injection site was graded as mild: hurt if gently touched, moderate: hurt if gently touched, with crying, severe: caused limitation of limb movement and Grade 4 (potentially life threatening): emergency room visit or hospitalization for severe pain at injection site. Grade 4 assessments were made by the investigator. Any local reaction: any mild, moderate, severe, or Grade 4 redness, swelling, or pain at the injection site.

Percentage of Participants With Local Reactions Within 7 Days After Dose 2
Day 1 through Day 7, where Day 1 is the day of Dose 2 administration (Visit 3 of study)

Local reactions included redness, swelling and pain at injection site. Redness and swelling were graded as mild: \> 0 to 2.0 cm, moderate: \>2.0 to 7.0 cm, severe: \>7.0 cm and Grade 4: necrosis or exfoliative dermatitis (redness) and necrosis (swelling). Pain at injection site was graded as mild: hurt if gently touched, moderate: hurt if gently touched, with crying, severe: caused limitation of limb movement and Grade 4 (potentially life threatening): emergency room visit or hospitalization for severe pain at injection site. Grade 4 assessments were made by the investigator. Any local reaction: any mild, moderate, severe, or Grade 4 redness, swelling, or pain at the injection site.

Percentage of Participants With Systemic Events Within 7 Days After Dose 1
Day 1 through Day 7, where Day 1 is the day of Dose 1 administration (Visit 1 of study)

Fever (oral temperature \>= 38 degree Celsius \[degC\]) was categorized as \>=38.0-38.4 degC, \>38.4-38.9 degC, \>38.9-40.0 degC and \>40.0 degC. Decreased appetite was graded as mild: decreased interest in eating, moderate: decreased oral intake, severe: refusal to feed. Drowsiness was graded as mild: increased/prolonged sleeping bouts, moderate: slightly subdued, interfered daily activity, severe: disabled, not interested in daily activity. Irritability was graded as mild: easily consolable, moderate: required increased attention, severe: inconsolable, crying couldn't be comforted. Grade 4 decreased appetite, drowsiness and irritability events led to emergency room visit or hospitalization and were classified by investigator/medically qualified person. Any systemic event: any fever, decreased appetite, drowsiness, irritability.

Percentage of Participants With Systemic Events Within 7 Days After Dose 2
Day 1 through Day 7, where Day 1 is the day of Dose 2 administration (Visit 3 of study)

Fever (oral temperature \>= 38 degC) was categorized as \>=38.0-38.4 degC, \>38.4-38.9 degC, \>38.9-40.0 degC and \>40.0 degC. Decreased appetite was graded as mild: decreased interest in eating, moderate: decreased oral intake, severe: refusal to feed. Drowsiness was graded as mild: increased/prolonged sleeping bouts, moderate: slightly subdued, interfered daily activity, severe: disabled, not interested in daily activity. Irritability was graded as mild: easily consolable, moderate: required increased attention, severe: inconsolable, crying couldn't be comforted. Grade 4 decreased appetite, drowsiness and irritability events led to emergency room visit or hospitalization and were classified by investigator/medically qualified person. Any systemic event: any fever, decreased appetite, drowsiness, irritability.

Percentage of Participants With Adverse Events (AEs) From Dose 1 Through 1 Month After Dose 2
From Dose 1 through 1 month after Dose 2 [up to approximately 3.7 months]

An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Results excluded local reactions and systemic events data.

Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 Through 1 Month After Dose 2
From Dose 1 through 1 month after Dose 2 [up to approximately 3.7 months]

An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was an AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or nonpathogenic; other situations as judged by investigator.

Secondary Endpoints
Geometric Mean Concentration (GMCs) of Pneumococcal Immunoglobulin G (IgG) at 1 Month After Dose 1
1 month after Dose 1
GMCs of Pneumococcal IgG at 1 Month After Dose 2
1 month after Dose 2
Percentage of Participants With Predefined IgG Concentrations at 1 Month After Dose 1
1 month after Dose 1
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
mPnC candidateEXPERIMENTALParticipants will receive the mPnC candidate at Visit 1 and Visit 3 (approximately 8 weeks apart). PCV10 will also be given at Visit 1.
mPnC controlACTIVE_COMPARATORParticipants will receive the mPnC control at Visit 1 and Visit 3 (approximately 8 weeks apart). PCV10 will also be given at Visit 1.
Interventions
NameTypeDescription
mPnC candidateBIOLOGICALmonovalent pneumococcal conjugate candidate
mPnC controlBIOLOGICALmonovalent pneumococcal conjugate control
Unlock Study Design Details
Eligibility Criteria
Age Range11 Months — 15 Months
SexALL
Healthy VolunteersYes
Study Sites11

Key Inclusion Criteria: * Toddlers ≥11 to ≤15 months of age at the time of consent. * Have received exactly 2 infant doses of PCV10 according to a local immunization schedule. * Healthy toddlers determined by clinical assessment, including medical history and clinical judgment, to be eligible for t...

Countries:FinlandPoland
Unlock Eligibility Criteria